Melius Pharma is a Swedish company founded in 2021 focused on the development of new treatments for interstitial lung diseases.
The company’s lead project for chronic cough in idiopathic pulmonary fibrosis is set to enter a Phase IIa clinical proof of concept study. Chronic cough is a serious symptom in idiopathic pulmonary fibrosis that severely affects the quality of life in patients suffering from this disease. Median survival for patients after diagnosis is 3–5 years with current treatments according to the company.
Melius Pharma says its drug candidate is a new chemical entity benefiting from more than 20 years of safety data in man as well as efficacy data from both clinical and preclinical cough studies.
HOVANA is a digital biology company tackling translational dysfunction as a driver of serious diseases. Leveraging insights into cellular reprogramming, HOVANA is inventing a new class of genomic medicines that …
Founded in 2022, Couragene is a biotechnology company developing first-in-class in vivo genetic therapies using its proprietary delivery platforms. The company's technology holds potential for developing gene therapies for brain …
Function Oncology is a precision medicine company advancing a CRISPR-powered personalized functional genomics platform to understand cancer in unprecedented and patient-specific detail. By moving beyond measuring gene sequence to measuring …
Founded in 2023, Mallia Therapeutics is a biopharmaceutical company developing soluble CD83 (sCD83) for the treatment of hair loss. sCD83, which was discovered as an immune modulator by Mallia co-founder …
